NIP
ACRS icon

Nicholas Investment Partners’s Aclaris Therapeutics ACRS Stock Holding History

Nicholas Investment Partners’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-68,489
Closed -$1.86M – 253
2016
Q4 		$1.86M Buy
68,489
+21,767
+47% +$555K 0.14% 234
2016
Q3 		$1.2M Buy
+46,722
New +$991K 0.08% 280

Other funds holding ACRS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nicholas Investment Partners's ACRS Position: Q1 2017 in Review

Nicholas Investment Partners sold out of Aclaris Therapeutics (ACRS) in Q1 2017, closing a stake of 68,489 shares — an estimated $1.86M sold.

Nicholas Investment Partners first reported a position in ACRS in Q3 2016 and held it in 2 quarters. The position peaked at $1.86M in Q4 2016. 110 funds tracked by Wall St. Rank hold ACRS as of Q1 2017.

  • Nicholas Investment Partners reported no remaining Aclaris Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Nicholas Investment Partners sold 68,489 Aclaris Therapeutics shares in Q1 2017, an estimated $1.86M.
  • Nicholas Investment Partners first reported a position in Aclaris Therapeutics in Q3 2016 and held it in 2 quarters.
  • Nicholas Investment Partners's Aclaris Therapeutics position peaked at $1.86M in Q4 2016.
  • 110 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2017.

Based on Nicholas Investment Partners's 13F filing for Q1 2017, filed 15 May 2017.